

Developing iPSC-derived cellular assays of R155H p97/VCP to assess treatment a rare degenerative disorder

Tsui-Fen Chou

Harbor-UCLA and LA BioMed

05/18/218

IBMPFD (Inclusion body myopathy with Paget disease and frontotemporal dementia)



- Affect muscles, bones, and brain.
- Muscle weakness (myopathy) can affect respiratory and heart muscles, leading to life-threatening breathing difficulties.
- Weaken bones, resulting in pain, misshapen bones, fractures.
- Damages parts of the brain that control reasoning, personality, social skills, speech, and language.

<http://www.usnon.com/genetics-of-pagets-disease-of-bone-like-disorders-inclusion-body-myopathy-pagets-disease-and-frontotemporal-dementia.htm>

p97/Cdc48/VCP

AAA ATPase (ATPase associated with diverse cellular activities)

p97 is essential, highly conserved, and abundant

The first substrate: ubiquitin- β -galactosidase fusion protein*

Play a critical role in the degradation of misfolded proteins
endoplasmic reticulum-associated degradation (ERAD)


Other cellular processes including:

Golgi membrane reassembly, membrane transport, myofibril assembly, cell division, formation of protein aggregates, autophagosome maturation


Mutation of p97 causes Inclusion Body Myopathy associated with Paget's disease of bone and Frontotemporal Dementia (IBMPFD) and Amyotrophic Lateral Sclerosis (ALS) known as Lou Gehrig's disease.

*Ghislain et. al., *EMBO J.* (1996), 15, 4884

p97/VCP regulates protein homeostasis



Disease Mutations of p97




Selective mutant p97 modulator


➤ Small molecule inhibitors/activators **IBMPFD mutants p97-cofactor complex**

High throughput screening at NIH/NCATS


(National Center for Advancing Translational Sciences)




Generation of R155H p97 iPSC from patient's fibroblast




BF




alkaline phosphatase




Hoechst




OCT4



SSEA4



Generation of the isogenic control iPSC lines using CRISPR





To change R155H +/- to WT (R155H -/-) in the patient derived iPSC cells

IDT: Alt-R® CRISPR-Cas9 System:

Cationic lipid delivery of CRISPR ribonucleoprotein complex into mammalian cells


iPSC-derived motor neurons

A



qPCR: expression level of markers for iPSC, iMP, and iMN

C



One of the R155H lines. We use p97/VCP as a negative control. Data were analyzed using GraphPad Prism software. N=3, T-test * p<0.05, ** p<0.01, *** p<0.001

Acknowledgement

Current lab members

Postdoctoral fellows: Feng Wang, Anna Luzzi

Staff Research associates: Betty Anderson, Chelsee Sauni

Former lab members

Postdoctoral fellows: Chen-Jie Fang, Shan Li, Gui Lin, Xiaoyi Zhang, Taiping Gan, Xi Hu

Staff research associates: Daniel Wong, Derek Moen

Funding

- Department of Pediatrics, Harbor-UCLA and LA BioMed
- The UCLA CTSI Grant UL1TR000124
- Henry L. Guenther Foundation (Orbitrap)
- NIH NCI Experimental Therapeutics (NExT) via Leidos Biomedical Research, Inc. Research Contracts
- NIH NICHD and NINDS (R01HD086596 and R01NS100815)
- TFC is a member of UCLA Jonsson Comprehensive Cancer Center